These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 22992516)
1. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Salphati L; Heffron TP; Alicke B; Nishimura M; Barck K; Carano RA; Cheong J; Edgar KA; Greve J; Kharbanda S; Koeppen H; Lau S; Lee LB; Pang J; Plise EG; Pokorny JL; Reslan HB; Sarkaria JN; Wallin JJ; Zhang X; Gould SE; Olivero AG; Phillips HS Clin Cancer Res; 2012 Nov; 18(22):6239-48. PubMed ID: 22992516 [TBL] [Abstract][Full Text] [Related]
2. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma. Salphati L; Alicke B; Heffron TP; Shahidi-Latham S; Nishimura M; Cao T; Carano RA; Cheong J; Greve J; Koeppen H; Lau S; Lee LB; Nannini-Pepe M; Pang J; Plise EG; Quiason C; Rangell L; Zhang X; Gould SE; Phillips HS; Olivero AG Drug Metab Dispos; 2016 Dec; 44(12):1881-1889. PubMed ID: 27638506 [TBL] [Abstract][Full Text] [Related]
3. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging. Salphati L; Shahidi-Latham S; Quiason C; Barck K; Nishimura M; Alicke B; Pang J; Carano RA; Olivero AG; Phillips HS Drug Metab Dispos; 2014 Jul; 42(7):1110-6. PubMed ID: 24754926 [TBL] [Abstract][Full Text] [Related]
4. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma. Becker CM; Oberoi RK; McFarren SJ; Muldoon DM; Pafundi DH; Pokorny JL; Brinkmann DH; Ohlfest JR; Sarkaria JN; Largaespada DA; Elmquist WF Neuro Oncol; 2015 Sep; 17(9):1210-9. PubMed ID: 25972455 [TBL] [Abstract][Full Text] [Related]
5. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515 [TBL] [Abstract][Full Text] [Related]
6. The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α. Heffron TP; Salphati L; Alicke B; Cheong J; Dotson J; Edgar K; Goldsmith R; Gould SE; Lee LB; Lesnick JD; Lewis C; Ndubaku C; Nonomiya J; Olivero AG; Pang J; Plise EG; Sideris S; Trapp S; Wallin J; Wang L; Zhang X J Med Chem; 2012 Sep; 55(18):8007-20. PubMed ID: 22946614 [TBL] [Abstract][Full Text] [Related]
7. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Opel D; Naumann I; Schneider M; Bertele D; Debatin KM; Fulda S Clin Cancer Res; 2011 May; 17(10):3233-47. PubMed ID: 21355080 [TBL] [Abstract][Full Text] [Related]
8. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. Sutherlin DP; Sampath D; Berry M; Castanedo G; Chang Z; Chuckowree I; Dotson J; Folkes A; Friedman L; Goldsmith R; Heffron T; Lee L; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Olivero A; Pang J; Prior WW; Salphati L; Sideris S; Tian Q; Tsui V; Wan NC; Wang S; Wiesmann C; Wong S; Zhu BY J Med Chem; 2010 Feb; 53(3):1086-97. PubMed ID: 20050669 [TBL] [Abstract][Full Text] [Related]
9. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Geng L; Shinohara ET; Kim D; Tan J; Osusky K; Shyr Y; Hallahan DE Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):263-71. PubMed ID: 16274936 [TBL] [Abstract][Full Text] [Related]
10. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007 [TBL] [Abstract][Full Text] [Related]
11. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma. Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598 [TBL] [Abstract][Full Text] [Related]
13. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292 [TBL] [Abstract][Full Text] [Related]
14. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451 [TBL] [Abstract][Full Text] [Related]
15. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725 [TBL] [Abstract][Full Text] [Related]
16. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968 [TBL] [Abstract][Full Text] [Related]
17. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy. Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857 [TBL] [Abstract][Full Text] [Related]
18. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052 [TBL] [Abstract][Full Text] [Related]
19. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. Kilic E; Kilic U; Wang Y; Bassetti CL; Marti HH; Hermann DM FASEB J; 2006 Jun; 20(8):1185-7. PubMed ID: 16641198 [TBL] [Abstract][Full Text] [Related]
20. Targeting the AKT pathway in glioblastoma. McDowell KA; Riggins GJ; Gallia GL Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]